Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash $ 32,748,337 $ 12,108,582
Inventory 806,407 577,690
Prepaid expenses and vendor deposits 338,108 141,221
Total current assets 33,892,852 12,827,493
Property and equipment, net 187,674 180,368
Right-to-use assets, net 409,982 714,342
Other assets:    
Patents, net 350,282 364,536
Trademarks 1,125 1,125
Prepaid expenses, long term 9,736 27,410
Deposits 101,839 101,839
Total assets 34,953,490 14,217,113
Current liabilities:    
Accounts payable and accrued expenses, including $154,500 and $39,674 to related parties as of September 30, 2020 and December 31, 2019, respectively 4,493,691 1,488,776
Dividends payable 69,835 128,478
Lease liability, short term 396,308 412,288
Total current liabilities 4,959,834 2,029,542
Lease liability, long term 22,365 311,131
Total debt 4,982,199 2,340,673
Commitments and contingencies (Note 11)
Preferred Stock 105,000 215,000
Equity:    
Preferred stock 0 0
Common stock, $0.001 par value, authorized 200,000,000 shares, 30,118,196 and 23,323,087 issued and outstanding as of September 30, 2020 and December 31, 2019, respectively 30,118 23,323
Additional paid in capital 175,228,334 115,910,058
Accumulated deficit (146,712,473) (104,786,769)
Total stockholders' equity attributable to BioSig Technologies, Inc. 28,545,979 11,146,612
Non-controlling interest 1,320,312 514,828
Total equity 29,866,291 11,661,440
Total liabilities and equity $ 34,953,490 $ 14,217,113